Show simple item record

dc.contributor.authorBayman, Neil A
dc.contributor.authorClive, A
dc.contributor.authorMaskell, N
dc.contributor.authorRyder, D
dc.contributor.authorTaylor, H
dc.contributor.authorFaivre-Finn, Corinne
dc.date.accessioned2019-12-09T17:08:12Z
dc.date.available2019-12-09T17:08:12Z
dc.date.issued2019en
dc.identifier.citationBayman N, Clive A, Maskell N, Ryder D, Taylor H, Faivre-Finn C. Reply to G. Zalcman et al. J Clin Oncol. 2019;37(29):2694-5.en
dc.identifier.doi10.1200/JCO.19.01520en
dc.identifier.urihttp://hdl.handle.net/10541/622518
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1200/JCO.19.01520en
dc.titleTrials of prophylactic irradiation of tracts: what is the appropriate end point? Replyen
dc.typeArticleen
dc.contributor.departmentThe Christie Hospital NHS FT, Manchesteren
dc.identifier.journalJournal of Clinical Oncologyen
dc.description.noteen


This item appears in the following Collection(s)

Show simple item record